The North America Intravenous Immunoglobulin Market is expected to witness market growth of 6.3% CAGR during the forecast period (2022-2028).
The immunoglobulins in intravenous immunoglobulin (IVIG) are pooled from the plasma of a thousand or more blood donors. They typically contain over most of unmodified IgG with intact Fc-dependent effector activities and just trace quantities of immunoglobulin A (IgA) or immunoglobulin M. (IgM). The benefits of an immune globulin intramuscular injection for the preventative treatment of patients with primary immunodeficiency disorders are well documented. In individuals with antibody deficiency, IVIG has therapeutic effects that go beyond antibody restoration. The range of inflammatory and autoimmune illnesses for which IVIG is utilized has skyrocketed particularly when given intravenously. From blistering skin ailments to transplant rejection and brain problems, these disorders are diverse.
The medical infrastructure of the region is witnessing an upsurge due to bringing and implementing new and advanced medical technologies to treat complex diseases. Such advanced technologies also comprises intravenous immunoglobulin. IVIg products are provided by the Canadian Blood Services. The products are available to Canadian blood banks located within hospitals, where they are dispensed to patients as prescribed by physicians. IVIg is currently used to treat primary and secondary immunodeficiencies as replacement therapy. IVIg is also used to treat autoimmune illnesses as an immunomodulatory treatment. There are six different approved signs (substitute and immunomodulatory) among the eight IVIg products available in Canada, comprising primary and secondary immunodeficiencies (PID/SID), each with many different primary pathologies.
Despite the fact that no single medication is indicated for all of these disorders in Canada, Canadian hospitals offer a number of IVIg medicines that are frequently interchanged. Canada has the biggest per-capita consumption of IVIg products in the world, and IVIg use has been gradually expanding in Canada for the past two decades.
The US market dominated the North America Intravenous Immunoglobulin Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $5,422.4 million by 2028. The Canada market is experiencing a CAGR of 8.7% during (2022-2028). Additionally, The Mexico market is expected to exhibit a CAGR of 7.8% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, and Others. Based on Application, the market is segmented into Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia & Myasthenia Gravis, Congenital AIDS & Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, Immune thrombocytopenia (ITP), and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Grifols, S.A., Takeda Pharmaceutical Company Limited, Baxter International, Inc., Biotest AG (Tiancheng International Investment Limited), LFB S.A., CSL Limited (CSL Behring), Octapharma AG, Kedrion S.p.A, and Bayer AG.
By Distribution Channel
The immunoglobulins in intravenous immunoglobulin (IVIG) are pooled from the plasma of a thousand or more blood donors. They typically contain over most of unmodified IgG with intact Fc-dependent effector activities and just trace quantities of immunoglobulin A (IgA) or immunoglobulin M. (IgM). The benefits of an immune globulin intramuscular injection for the preventative treatment of patients with primary immunodeficiency disorders are well documented. In individuals with antibody deficiency, IVIG has therapeutic effects that go beyond antibody restoration. The range of inflammatory and autoimmune illnesses for which IVIG is utilized has skyrocketed particularly when given intravenously. From blistering skin ailments to transplant rejection and brain problems, these disorders are diverse.
The medical infrastructure of the region is witnessing an upsurge due to bringing and implementing new and advanced medical technologies to treat complex diseases. Such advanced technologies also comprises intravenous immunoglobulin. IVIg products are provided by the Canadian Blood Services. The products are available to Canadian blood banks located within hospitals, where they are dispensed to patients as prescribed by physicians. IVIg is currently used to treat primary and secondary immunodeficiencies as replacement therapy. IVIg is also used to treat autoimmune illnesses as an immunomodulatory treatment. There are six different approved signs (substitute and immunomodulatory) among the eight IVIg products available in Canada, comprising primary and secondary immunodeficiencies (PID/SID), each with many different primary pathologies.
Despite the fact that no single medication is indicated for all of these disorders in Canada, Canadian hospitals offer a number of IVIg medicines that are frequently interchanged. Canada has the biggest per-capita consumption of IVIg products in the world, and IVIg use has been gradually expanding in Canada for the past two decades.
The US market dominated the North America Intravenous Immunoglobulin Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $5,422.4 million by 2028. The Canada market is experiencing a CAGR of 8.7% during (2022-2028). Additionally, The Mexico market is expected to exhibit a CAGR of 7.8% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, and Others. Based on Application, the market is segmented into Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia & Myasthenia Gravis, Congenital AIDS & Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, Immune thrombocytopenia (ITP), and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Grifols, S.A., Takeda Pharmaceutical Company Limited, Baxter International, Inc., Biotest AG (Tiancheng International Investment Limited), LFB S.A., CSL Limited (CSL Behring), Octapharma AG, Kedrion S.p.A, and Bayer AG.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacy
- Specialty Pharmacy
- Others
- Immunodeficiency Diseases
- Chronic Inflammatory Demyelinating Polyneuropathy
- Hypogammaglobulinemia
- Chronic Lymphocytic Leukemia & Myasthenia Gravis
- Congenital AIDS & Multifocal Motor Neuropathy
- Kawasaki Disease
- Guillain-Barre Syndrome
- Immune thrombocytopenia (ITP)
- Others
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Baxter International, Inc.
- Biotest AG (Tiancheng International Investment Limited)
- LFB S.A.
- CSL Limited (CSL Behring)
- Octapharma AG
- Kedrion S.p.A
- Bayer AG
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Intravenous Immunoglobulin Market by Distribution Channel
Chapter 4. North America Intravenous Immunoglobulin Market by Application
Chapter 5. North America Intravenous Immunoglobulin Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Baxter International, Inc.
- Biotest AG (Tiancheng International Investment Limited)
- LFB S.A.
- CSL Limited (CSL Behring)
- Octapharma AG
- Kedrion S.p.A
- Bayer AG
Methodology
LOADING...
